v3.25.2
Accrued Litigation Settlement Expenses
6 Months Ended
Jun. 30, 2025
Commitments and Contingencies Disclosure [Abstract]  
Accrued Litigation Settlement Expenses
7. Accrued Litigation Settlement Expenses
June 30, 2025December 31, 2024
CurrentNon currentTotalCurrentNon currentTotal
Accrued litigation settlement expenses
DOJ-related$51 $247 $298 $52 $296 $348 
Antitrust claims
20 — 20 24 — 24 
Opioid litigation
27 52 79 15 61 76 
Other— 16 
Total accrued litigation settlement expenses
$105 $299 $404 $99 $365 $464 
DOJ-related
In July 2020, the Company settled criminal and civil liability with the U.S. Department of Justice (DOJ), the U.S. Federal Trade Commission (FTC), and U.S. state attorneys general. A scheduled payment of $52 million was made during the six months ended June 30, 2025 with respect to this matter.
Opioid litigation
The accrual of $79 million at June 30, 2025 reflects the present value of the agreed amount in a settlement covering certain opioid litigation (including cases in the Opioid MDL). The provision is measured using a risk-free rate.
Antitrust claims
An installment of $5 million was paid in the six months ended June 30, 2025 in relation to the last remaining antitrust litigation. The remaining accrual of $20 million at June 30, 2025 reflects the NPV at the risk-free rate of the amounts to be paid in 2025. This final settlement resolves all of the Company’s remaining legacy antitrust litigation.
See Note 12. Commitments and Contingencies for additional information on legal matters.